Momenta Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Momenta Pharmaceuticals Inc.

MNTA 52.48

0.0%

Oct 2 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: mopgcw who wrote (2844)	9/24/2011 8:54:44 AM
From: IRWIN JAMES FRANKEL	Read Replies (1) of 3027

============= At one point the lawyers argued over whether certain evidence should be admitted at this late date in the trail. The evidence would have supported Dr. Wall’s point that different measurement techniques available at the time the patents were issued would actually yield entirely different estimates for molecular weight. The judge refused to allow Dr. Wall’s testimony regarding this evidence to be admitted, but the point was clear even without the formal admission of the evidence. In another instance the judge shut down a line of questioning that revolved around an unrelated patent and what it might teach about prior art knowledge, refocusing the lawyers on the core issues in the case. ================ That is pretty interesting. Could constitute a "tell". ================= Teva's patents on Copaxone should be found to NOT block mL. -- JMHO ij

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next